Cochlear Ltd
ASX:COH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
258.7
350.17
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cochlear Ltd
Cochlear Ltd
Cash & Cash Equivalents
Cochlear Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cochlear Ltd
ASX:COH
|
Cash & Cash Equivalents
AU$513.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
46%
|
CAGR 10-Years
25%
|
|
|
R
|
Respiri Ltd
ASX:RSH
|
Cash & Cash Equivalents
AU$762.9k
|
CAGR 3-Years
-54%
|
CAGR 5-Years
20%
|
CAGR 10-Years
-21%
|
|
|
ImpediMed Ltd
ASX:IPD
|
Cash & Cash Equivalents
AU$24.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Cash & Cash Equivalents
AU$27.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
37%
|
CAGR 10-Years
35%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Cash & Cash Equivalents
AU$6.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
28%
|
CAGR 10-Years
56%
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Cash & Cash Equivalents
AU$18.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Cochlear Ltd
Glance View
Cochlear Ltd. is a pioneering Australian company at the forefront of innovative hearing solutions, dedicated to transforming the lives of individuals with hearing loss. Founded in 1981, the company specializes in the development and manufacture of advanced cochlear implants, which are electronic devices that bypass damaged hair cells in the cochlea and stimulate the auditory nerve directly, enabling patients to perceive sound. With a global footprint, Cochlear serves a diverse range of customers, from newborns to adults, and its products are supported by a robust body of clinical evidence and state-of-the-art technology. As a leader in the industry, Cochlear has established strong relationships with healthcare professionals and patients alike, creating a loyal customer base that drives long-term growth. For investors, Cochlear presents a compelling opportunity in the healthcare sector, characterized by its relentless focus on research and development, which ensures a pipeline of innovative products that keep it ahead of competitors. The company’s financial performance has shown resilience, with steady revenue growth and a solid margin due to its unique position in the global market, coupled with a diversified revenue model that includes both product sales and ongoing service agreements. As the global population ages and awareness of hearing loss increases, Cochlear is well positioned to capitalize on the growing demand for its products. With a commitment to sustainability and corporate responsibility, Cochlear not only seeks to enhance shareholder value but also strives to make a meaningful impact on the lives of those with hearing difficulties, aligning its business success with social good.
See Also
What is Cochlear Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
513.6m
AUD
Based on the financial report for Jun 30, 2024, Cochlear Ltd's Cash & Cash Equivalents amounts to 513.6m AUD.
What is Cochlear Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
25%
Over the last year, the Cash & Cash Equivalents growth was -8%. The average annual Cash & Cash Equivalents growth rates for Cochlear Ltd have been -6% over the past three years , 46% over the past five years , and 25% over the past ten years .
You don't have any saved screeners yet
